Recently, some authors explored JAK2 MPN driver mutations in endothelial progenitor cells (EPCs) or mature endothelial cells (ECs), finding that 70% of PMF patients shared mutations between hematopoietic stem/progenitor cells (HSPCs) and circulating ECs (CECs). Here, JAK2 is linked to myeloproliferative disorder.